Dysautonomia (Autonomic Dysfunction) – Pipeline Review, H2 2012

Dysautonomia (Autonomic Dysfunction) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Dysautonomia (Autonomic Dysfunction) - Pipeline Review, H2 2012', provides an overview of the Dysautonomia (Autonomic Dysfunction) therapeutic pipeline. This report provides information on the therapeutic development for Dysautonomia (Autonomic Dysfunction), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dysautonomia (Autonomic Dysfunction). 'Dysautonomia (Autonomic Dysfunction) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dysautonomia (Autonomic Dysfunction).
- A review of the Dysautonomia (Autonomic Dysfunction) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dysautonomia (Autonomic Dysfunction) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dysautonomia (Autonomic Dysfunction).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dysautonomia (Autonomic Dysfunction) pipeline depth and focus of Dysautonomia (Autonomic Dysfunction) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dysautonomia (Autonomic Dysfunction) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Dysautonomia (Autonomic Dysfunction) 7
Dysautonomia (Autonomic Dysfunction) Therapeutics under Investigation by Universities/Institutes 9
Early Clinical Stage Products 10
Comparative Analysis 10
Dysautonomia (Autonomic Dysfunction) Therapeutics – Products under Investigation by Universities/Institutes 11
Dysautonomia (Autonomic Dysfunction) – Therapeutics Assessment 12
Assessment by Monotherapy Products 12
Assessment by Combination Products 13
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Drug Profiles 18
Entacapone + Propranolol - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Acetazolamide - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Atomoxetine - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Clonidine - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Entacapone - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Indomethacin - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Mecamylamine - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Memantine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Midodrine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Modafinil - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Sertraline - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Atomoxetine + Propranolol - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Isosorbide Dinitrate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Octreotide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Modafinil + Propranolol - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Dysautonomia (Autonomic Dysfunction) Therapeutics – Discontinued Products 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables
Number of Products Under Development for Dysautonomia (Autonomic Dysfunction), H2 2012 7
Products under Development for Dysautonomia (Autonomic Dysfunction) – Comparative Analysis, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 9
Comparative Analysis by Early Clinical Stage Development, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Assessment by Monotherapy Products, H2 2012 12
Assessment by Combination Products, H2 2012 13
Assessment by Stage and Route of Administration, H2 2012 15
Assessment by Stage and Molecule Type, H2 2012 17
Dysautonomia (Autonomic Dysfunction) Therapeutics – Discontinued Products 33

List of Figures
Number of Products under Development for Dysautonomia (Autonomic Dysfunction), H2 2012 7
Products under Development for Dysautonomia (Autonomic Dysfunction) – Comparative Analysis, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Early Clinical Stage Products, H2 2012 10
Assessment by Monotherapy Products, H2 2012 12
Assessment by Combination Products, H2 2012 13
Assessment by Route of Administration, H2 2012 14
Assessment by Stage and Route of Administration, H2 2012 15
Assessment by Molecule Type, H2 2012 16
Assessment by Stage and Molecule Type, H2 2012 17